8-K: Ovid Therapeutics Reports Positive Phase 1 OV350 Results

Ovid Therapeutics announced positive Phase 1 results for its KCC2 direct activator, OV350, supporting the advancement of its oral KCC2 portfolio.

Summary

• The Phase 1 study of OV350, the first-ever KCC2 direct activator dosed in humans, met its primary objectives to evaluate safety, tolerability, and pharmacokinetics.
• OV350 demonstrated a good safety profile with no treatment-related serious adverse events (SAEs) or treatment-related laboratory findings.
• Exploratory quantitative electrophysiology (qEEG) results suggested central activity and spectral power consistent with expected physiological effects of KCC2 modulation, aligning with expected drug exposure in the brain.
• Pharmacokinetics for OV350 were as predicted, providing valuable information for future KCC2 development programs.
• Ovid Therapeutics will not advance OV350 IV further in the clinic, instead prioritizing the development of oral KCC2 direct activators.
• OV4071, an oral KCC2 direct activator, is 20-fold more potent than OV350 in pharmacodynamic models.
• A regulatory submission for a Phase 1/1b clinical trial of OV4071 is on track for Q1 2026, with clinical studies planned to initiate in Q2 2026.
• OV4071 is being developed for the treatment of psychosis associated with Parkinson's disease and Lewy body dementia, and potentially other neuropsychiatric conditions like schizophrenia and psychoses/agitation in Alzheimer's disease.

Sentiment

Score: 8

Explanation: The Phase 1 study successfully met its primary endpoints for safety, tolerability, and pharmacokinetics for a first-in-class mechanism. This de-risks the KCC2 target and provides a clear path forward for more potent oral candidates like OV4071, which has a defined clinical development plan for high-unmet-need indications.

Positives

• OV350 demonstrated a good safety profile with no treatment-related serious adverse events (SAEs) or laboratory findings.
• The Phase 1 study met its primary objectives for safety, tolerability, and pharmacokinetics for a first-in-class KCC2 direct activator.
• Exploratory qEEG results indicated central activity and spectral power consistent with KCC2 modulation, suggesting the drug reached its target in the brain.
• Pharmacokinetics for OV350 were as predicted, providing crucial data for the development of future KCC2 programs.
• The positive results support the advancement of Ovid's portfolio of oral KCC2 direct activators, including the more potent OV4071.
• OV4071 is an oral direct activator that is 20-fold more potent than OV350 in pharmacodynamic models.
• Regulatory submission for a Phase 1/1b clinical trial of OV4071 is on track for Q1 2026, with clinical studies planned for Q2 2026.
• KCC2 is identified as an entirely new therapeutic target in the brain, potentially acting as a 'master switch' to curb neural hyperexcitability.

Negatives

• The most frequent treatment-emergent adverse event (AE) associated with OV350 was headache.
• Nausea and vomiting occurred in a subset of participants experiencing headache, believed to be caused by secondary off-target pharmacology unique to OV350.
• Ovid Therapeutics does not intend to advance OV350 IV further in the clinic, choosing to prioritize oral formulations.

Risks

• Uncertainties inherent in the preclinical and clinical development and regulatory approval processes.
• Impediments to Ovid's ability to achieve expected benefits of cost-savings efforts.
• Risks related to Ovid's ability to achieve its financial objectives.
• The risk that Ovid may not be able to realize the intended benefits of its business strategy.
• Risks related to Ovid's ability to identify business development targets or strategic partners.
• Risks related to Ovid's ability to enter into strategic transactions on favorable terms.
• Risks related to Ovid's ability to consummate and realize the benefits of any business development transactions.
• Unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions.

Future Outlook

Ovid expects to submit a regulatory application for a Phase 1/1b study of OV4071 in Q1 2026 and plans to initiate clinical studies in Q2 2026, targeting psychosis associated with Parkinson's disease and Lewy body dementia. The company also plans to explore OV4071's effects in other neuropsychiatric conditions like schizophrenia and psychoses/agitation associated with Alzheimer's disease. Additionally, Ovid is advancing next-generation KCC2 activators from its proprietary library for both oral and injectable formulations.

Management Comments

• "OV350 is a valuable tool program that supported human safety for drugging KCC2, an entirely new therapeutic target in the brain, which could be a master switch to curb neural hyperexcitability." Meg Alexander, President and Chief Operating Officer.
• "The results from this study give us confidence that this new mechanistic class is amenable for further development and reinforces our decision earlier this year to invest in the development of additional direct activator molecules and formulations for chronic use, including OV4071, the first oral KCC2 direct activator." Meg Alexander.
• "We expect to submit our regulatory application for a Phase 1/1b study of OV4071 in Q1 2026 and plan to initiate clinical studies in Q2 2026." Meg Alexander.

Industry Context

The development of KCC2 direct activators represents a differentiated, mechanism-based approach to treating serious neurological and neuropsychiatric conditions characterized by neuronal hyperexcitability. KCC2 is described as an 'entirely new therapeutic target' and a 'master switch' to curb neural hyperexcitability, positioning Ovid at the forefront of a novel therapeutic area for brain disorders. The strategic focus on indications like psychosis in Parkinson's disease and Lewy body dementia addresses high unmet medical needs where existing treatments, such as traditional atypical antipsychotics, are often contraindicated, offering a potentially significant market opportunity.

Comparison to Industry Standards

• The target indications for OV4071, such as psychosis associated with Parkinson's disease and Lewy body dementia, are noted to have 'high unmet need, validated endpoints, an established regulatory pathway,' indicating alignment with industry standards for drug development in these areas.
• The statement that 'traditional atypical antipsychotics are typically contraindicated' for these conditions highlights a potential competitive advantage for Ovid's KCC2 activators if successful, as they could fill a critical therapeutic gap.

Stakeholder Impact

• Shareholders: Positive impact due to successful Phase 1 results, de-risking of a novel therapeutic target, and clear advancement of a more potent oral pipeline candidate (OV4071) into clinical trials for high-unmet-need indications.
• Patients: Potential for new therapeutic options for serious neurological and neuropsychiatric conditions, particularly those with limited or contraindicated existing treatments.
• Employees: Continued progress in the pipeline supports ongoing research and development efforts and strategic focus.

Next Steps

• Regulatory submission for a Phase 1/1b clinical trial of OV4071 in Q1 2026.
• Initiation of clinical studies for OV4071 in Q2 2026 for psychosis associated with Parkinson's disease and Lewy body dementia.
• Characterization of pharmacodynamic effects of OV4071 in additional neuropsychiatric conditions, including schizophrenia and psychoses or agitation associated with Alzheimer's disease.
• Advancing next-generation KCC2 activators from Ovid's proprietary library for oral and injectable formulations.
• Submission of OV350 study results for a future congress.

Key Dates

Recommendation

The successful Phase 1 results for OV350 validate KCC2 as a novel therapeutic target and de-risk the mechanism of action. The company's strategic pivot to focus on the more potent oral candidate, OV4071, with a clear development pathway into high-unmet-need indications like psychosis in Parkinson's and Lewy body dementia, presents a strong growth opportunity. The planned Q1 2026 regulatory submission and Q2 2026 clinical trial initiation for OV4071 provide near-term catalysts. While early-stage, the data supports a positive outlook for Ovid's KCC2 franchise.

Keywords

Ovid Therapeutics, OV350, OV4071, KCC2 activator, Phase 1 study, Clinical trial, Neurological disorders, Brain disorders, Neural excitability, Pharmacokinetics, Safety profile, Biopharmaceutical, Psychosis, Parkinson's disease, Lewy body dementia, Schizophrenia, Alzheimer's disease